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While the HIV pandemic continues to cause suffering, death,
and economic destruction, there have been small successes that
warrant continued hope and efforts to improve the lives of those
affected. The incidence and prevalence of HIV is declining in
several regions of Africa, and approximately three million Africans
are now on combination antiretroviral (ARV) therapy. A great deal
of credit should be given to the generous ﬁnancial commitment of
the United States Government in recent years, particularly through
the US Presidents Emergency Plan for AIDS Relief (PEPFAR). This
support has contributed to the development of health care
infrastructure throughout the continent, the provision of anti-
retrovirals and other pharmaceutical products necessary to
manage HIV-related opportunistic infections, and training pro-
grams that have expanded the expertise in HIV care that is needed
for the foreseeable future.1,2
In some regions of Africa, the status of the epidemic has
improved markedly from the pre-2004 (pre-PEPFAR) period, when
few had access to ARVs.3 Nevertheless, we look to the future with
concern and uncertainty, and wonder whether to be optimistic or
pessimistic about the sustainability of these efforts. The recent
large increase in the PEPFAR ﬁnancial allocation for the next ﬁve
years was enthusiastically embraced by those working in the HIV
ﬁeld and will save many lives. However, a year past the
announcement of increased funding, the on-the-ground realities
look dimmer than before the announcement.4 The increased
funding has not turned into wider access to ARVs in most African
settings, and increased patient needs are resulting in patients
being turned away from ARV access.5 A reasonable explanation for
the poor resurgence of funding by PEPFAR and The Global Fund to
Fights AIDS, TB andMalaria (Global Fund) is the current worldwide
economic recession. As examples of downsizing treatment begin to
receive attention,5 how can the HIV academic and service provider
populations ensure that treatment is sustained and health
infrastructure remains? History provides a long list of evidence
that the funding priorities of the developed world change over
time, sometimes abruptly, and are highly dependent on the
philosophies of the elected governments. There are several
important human capacity and infrastructure investments that
may help alleviate the impact of reduced funding.
Firstly, expertise in the provision of HIV care now is well
established in Africa. The vast majority of the training is done by
local experts and is not dependent on outside expertise. Therefore,
we are conﬁdent that the administrative and medical skills
required for a sustained and effective local and national response
to the HIV epidemic can survive the loss of large-scale
international funding. Current funding should focus on developing
human and program resources focused on self-reliance and
sustainability.1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
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HIV care or in the administration of health care systems have
contributed their time to the African continent, even before there
was any funding available for these purposes. We are optimistic
that this resource is sustainable, irrespective of changes in funding
allocation and changes in foreign policy.We are also conﬁdent that
as guests in these countries we are getting better at providing this
expertise in a fashion that is respectful and which truly facilitates
our colleagues’ work in Africa. Although the desire to exchange our
HIV knowledge and experience is not likely to dissipate, a key
guiding principle and ultimate goal in the future should be to
transfer our expertise so effectively to our African colleagues that
we are eventually no longer required.
Secondly, a focus of the effort against HIV is on prevention, with
key elements including abstinence, limiting the number of sex
partners, condom use, mother-to-child transmission prevention
strategies, and male circumcision. None of these interventions
alone are likely to meet with large-scale success, but in
combination they represent a pragmatic, common sense-based,
and relatively inexpensive collection of preventative measures
that can be broadly implemented, do not require high level
technology, and are not dependant on antiretroviral availability.6
These measures are sustainable despite predicted future ﬂuctua-
tions in international funding.
Thirdly, a loss of funding will critically impact on the ability to
purchase antiretrovirals. However, the capacity to produce
antiretrovirals has been developed in Africa and the increasing
availability of cheaper Asian-produced generics will serve a critical
role in withstanding the negative impact of reduced funding on the
ability to maintain those on therapy and initiate new patients on
treatment.7 There is a need for pragmatic, patent-challenging
examples of drug-development. Within most African countries,
patent law is not a major concern, so efforts to break patents may
be an important step forward,8 in particular in settings that are
already out of favor with the international community, but on
favorable terms within Africa, such as Zimbabwe or Sudan.
Although funding is currently being reduced, there are several
reasons why we believe that complete elimination of ﬁnancial
support of HIV in Africa is unlikely, barring a complete ﬁnancial
collapse of the Western economies. Our governments recognize
the value of facilitating the security of African nations, if for no
other reason but the egocentric need to have stable trading
partners and political allies in this region. Concerns that infectious
diseases represent a national security risk and are a guiding tenant
of much foreign policy should provide some assurance to those
livingwithHIV in Africa that ﬁnancial supportwill not evaporate in
the very near future.
A recent movement within the international health community
has been the accusation that AIDS receives an unreasonable
proportion of funding compared to other endemic diseases,9
resulting in claims that AIDS should not be exceptional.10Whileweses. Published by Elsevier Ltd. All rights reserved.
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important examples where AIDS is an exceptional disease and
requires exceptional funding. Countries such as Swaziland,
Botswana, and South Africa represent such examples, as more
than 30% of their populations have a terminal disease if left
untreated. The impact of this kind of rapid mortality from
untreated infections will have repercussions for generations to
come.
The past history of successful grassroots HIV/AIDS responses
throughout Africa argues that to be optimistic for the future is to
not be naive. The AIDS Services Organization (TASO) in Ugandawas
forged without funding by a handful of dedicated individuals
willing to face the challenges of this epidemic.11 In our experience,
this resource of compassion and selﬂessness is inexhaustible and
capable of surviving the predictable changes in foreign policy and
funding commitment. For our part, as with other large scale
programs such as vaccination campaigns or efforts to control
malaria, vigilance will be necessary to protect against debilitating
reductions in HIV funding, despite changing priorities and
conceptions that gains made with HIV in Africa will not be lost
if we neglect our obligations. Increased reliance on African-
produced ARVs is critical to protecting the well-being of those
already on highly active antiretroviral therapy (HAART). Pragmatic
approaches focused on HIV prevention that are technology-
independent must not be forgotten.
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